GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lepu Biopharma Co Ltd (HKSE:02157) » Definitions » Return-on-Tangible-Asset

Lepu Biopharma Co (HKSE:02157) Return-on-Tangible-Asset : -23.79% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Lepu Biopharma Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lepu Biopharma Co's annualized Net Income for the quarter that ended in Dec. 2024 was HK$-467.5 Mil. Lepu Biopharma Co's average total tangible assets for the quarter that ended in Dec. 2024 was HK$1,965.1 Mil. Therefore, Lepu Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -23.79%.

The historical rank and industry rank for Lepu Biopharma Co's Return-on-Tangible-Asset or its related term are showing as below:

HKSE:02157' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -62.31   Med: -40.72   Max: -1.14
Current: -22.21

During the past 6 years, Lepu Biopharma Co's highest Return-on-Tangible-Asset was -1.14%. The lowest was -62.31%. And the median was -40.72%.

HKSE:02157's Return-on-Tangible-Asset is ranked better than
62.54% of 1495 companies
in the Biotechnology industry
Industry Median: -36.98 vs HKSE:02157: -22.21

Lepu Biopharma Co Return-on-Tangible-Asset Historical Data

The historical data trend for Lepu Biopharma Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lepu Biopharma Co Return-on-Tangible-Asset Chart

Lepu Biopharma Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial -43.28 -62.31 -38.15 -1.14 -22.55

Lepu Biopharma Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.23 -14.66 12.92 -20.29 -23.79

Competitive Comparison of Lepu Biopharma Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, Lepu Biopharma Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lepu Biopharma Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Lepu Biopharma Co's Return-on-Tangible-Asset falls into.


;
;

Lepu Biopharma Co Return-on-Tangible-Asset Calculation

Lepu Biopharma Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-439.215/( (2024.71+1871.531)/ 2 )
=-439.215/1948.1205
=-22.55 %

Lepu Biopharma Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-467.526/( (2058.736+1871.531)/ 2 )
=-467.526/1965.1335
=-23.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


Lepu Biopharma Co  (HKSE:02157) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Lepu Biopharma Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Lepu Biopharma Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lepu Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
No. 651, Lianheng Road, Minhang District, Shanghai, CHN, 201112
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in Mainland China. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. The company generates the majority of its revenue from the Sale of pharmaceutical products. The company also generates a small portion of its revenue from Licensing income.
Executives
Hu Chaohong 2201 Interest of corporation controlled by you
Miracogen Inc. 2201 Interest of corporation controlled by you
Miracogen Limited 2101 Beneficial owner
Pu Zhongjie 2201 Interest of corporation controlled by you
Pu Jue 2201 Interest of corporation controlled by you
Hao Chunmei 2202 Interest of your spouse
Su Rongyu 2101 Beneficial owner
Cereblue Limited 2201 Interest of corporation controlled by you
Bei Jing Hou De Yi Min Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Hou De Yi Min Xin Xi Ke Ji You Xian Gong Si 2101 Beneficial owner
Le Pu Bei Jing Yi Liao Qi Xie Gu Fen You Xian Gong Si 2101 Beneficial owner
Lv Yuan Shang Hai Ke Ji You Xian Gong Si 2101 Beneficial owner

Lepu Biopharma Co Headlines

No Headlines